Rezolute (NASDAQ:RZLT) Upgraded to Buy at Craig Hallum

Rezolute (NASDAQ:RZLT) was upgraded by Craig Hallum from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a $7.00 price objective on the stock, up from their previous price objective of $4.00. Craig Hallum’s target price points to a potential upside of 67.46% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Wall Street Zen lowered shares of Rezolute from a “hold” rating to a “sell” rating in a research note on Tuesday, June 30th. Maxim Group lifted their price target on Rezolute from $10.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. HSBC raised Rezolute to a “buy” rating in a research report on Friday. Zacks Research raised Rezolute from a “strong sell” rating to a “hold” rating in a research report on Friday, August 14th. Finally, Citizens Jmp raised shares of Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 price objective on the stock in a research report on Wednesday, June 3rd. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.62.

Rezolute Stock Performance

Shares of NASDAQ RZLT opened at $4.18 on Tuesday. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.46. The firm has a market capitalization of $404.29 million, a price-to-earnings ratio of -5.50 and a beta of 0.60. The stock has a 50 day moving average price of $4.57 and a 200 day moving average price of $4.03.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). Analysts forecast that Rezolute will post -0.52 earnings per share for the current year.

Institutional Investors Weigh In On Rezolute

A number of large investors have recently modified their holdings of RZLT. Dimensional Fund Advisors LP raised its position in shares of Rezolute by 273.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company’s stock valued at $1,617,000 after purchasing an additional 388,346 shares during the last quarter. Siren L.L.C. purchased a new stake in Rezolute during the 1st quarter worth approximately $10,151,000. Jennison Associates LLC purchased a new stake in Rezolute during the 1st quarter worth approximately $10,489,000. Bank of New York Mellon Corp acquired a new position in Rezolute during the 2nd quarter valued at approximately $1,104,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Rezolute during the 4th quarter valued at approximately $494,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Trending Headlines about Rezolute

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright projects Rezolute could reach positive earnings of $1.42 per share in fiscal 2030 and $2.94 per share in fiscal 2031, substantially improving the company’s long-term earnings potential.
• Positive Sentiment: The firm raised its fiscal 2029 EPS forecast to a loss of $0.14 from a loss of $0.17, while maintaining its Buy rating and $10 price target—well above recent trading levels.
• Neutral Sentiment: HC Wainwright expects Rezolute to remain unprofitable through fiscal 2029, with estimates of a $0.57-per-share loss in fiscal 2027, a $0.34 loss in fiscal 2028, and a $0.14 loss in fiscal 2029. The analyst forecasts a return to positive quarterly earnings in the fourth quarter of 2028.
• Negative Sentiment: The analyst lowered its fiscal 2027 EPS forecast to a $0.57 loss from $0.45, cut fiscal 2028 to a $0.34 loss from $0.33, and reduced estimates for the first two quarters of fiscal 2027 and the fourth quarter of fiscal 2027. These revisions point to higher expected near-term losses and may limit the stock’s upside until Rezolute’s pipeline generates revenue.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.